Emergent Bio licenses Ligand Pharma's technology to augment its discovery of new antibodies - Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) | Seeking Alpha

Ligand Pharmaceuticals  enters into a global license agreement with Emergent BioSolutions under which Emergent will use Ligand's OmniRat, OmniMouse and OmniFlic technologies to discover fully human mono- and bispecific antibodies.